AR072184A1 - Derivados de oxadiazol como agonistas del receptor s1p1 - Google Patents
Derivados de oxadiazol como agonistas del receptor s1p1Info
- Publication number
- AR072184A1 AR072184A1 ARP090102219A ARP090102219A AR072184A1 AR 072184 A1 AR072184 A1 AR 072184A1 AR P090102219 A ARP090102219 A AR P090102219A AR P090102219 A ARP090102219 A AR P090102219A AR 072184 A1 AR072184 A1 AR 072184A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- hydrogen
- difluoromethoxy
- Prior art date
Links
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 title 1
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical class C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 3
- -1 trifluoromethoxy, difluoromethoxy Chemical group 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000004866 oxadiazoles Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003235 pyrrolidines Chemical class 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
Abstract
La presente se refiere a derivados de oxadiazol que tienen actividad farmacologica, a procesos para su preparacion, a composiciones farmaceuticas que los contienen y a su uso en el tratamiento de diferentes trastornos, en particular trastornos autoinmunes. Reivindicacion 1: Un compuesto de formula (1) o una sal del mismo en la que R5 es como en formula (2) y est unido en una cualquiera de las posiciones 4, 5, 6 o 7 del grupo indol; A es un fenilo o un anillo heteroarilo de 5 o 6 miembros; R1 es hidrogeno o hasta tres sustituyentes independientemente seleccionados de halogeno, alquilo C1-6, cicloalquilo C3-6, alcoxi C1-6, cicloalquiloxi C3-6, trifluorometoxi, difluorometoxi, trifluorometilo, ciano, nitro, piperidina opcionalmente sustituida, pirrolidina opcionalmente sustituida, fenilo opcionalmente sustituido y anillos heteroar¡licos de 5 o 6 miembros opcionalmente sustituidos; cuando R1 es fenilo, piperidina, pirrolidina o un anillo heteroar¡lico de 5 o 6 miembros, puede estar sustituido con hasta tres sustituyentes seleccionados de halogeno, alquilo C1-6, alcoxi C1-6, trifluorometoxi, difluorometoxi, cicloalquilo C3-6, trifluorometilo y ciano; R2 es hidrogeno o representa hasta tres sustituyentes seleccionados independientemente entre halogeno, alquilo C1-4, alcoxi C1-4, trifluorometoxi, difluorometoxi, trifluorometilo y ciano; uno de R3 y R4 es hidrogeno o alquilo C1-6 y el otro es Z-COOH o alquilo C16-OH; Z est ausente o es alquilo C1-6 o alquenilo C2-6; cuando Z es alquilo C1-6, est opcionalmente interrumpido con ciclopropilo, piperidinilo, azetidinilo, pirrolidinilo, N u O y opcionalmente sustituido con O, ciclopropilo, halogeno o metilo, cuando Z es alquenilo C2-6 est opcionalmente sustituido con metilo, R6 es hidrogeno o alquilo C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0811449A GB0811449D0 (en) | 2008-06-20 | 2008-06-20 | Compounds |
| GB0909744A GB0909744D0 (en) | 2009-06-05 | 2009-06-05 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072184A1 true AR072184A1 (es) | 2010-08-11 |
Family
ID=41011874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102219A AR072184A1 (es) | 2008-06-20 | 2009-06-18 | Derivados de oxadiazol como agonistas del receptor s1p1 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8217028B2 (es) |
| EP (1) | EP2297139A1 (es) |
| JP (1) | JP2011524880A (es) |
| AR (1) | AR072184A1 (es) |
| TW (1) | TW201011013A (es) |
| UY (1) | UY31922A (es) |
| WO (1) | WO2009153307A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31922A (es) * | 2008-06-20 | 2010-01-05 | Glaxo Group Ltd | Compuestos |
| WO2010043000A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators and their use thereof |
| AU2009304596A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| GB0910667D0 (en) * | 2009-06-19 | 2009-08-05 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
| TW201245185A (en) | 2011-04-01 | 2012-11-16 | Lundbeck & Co As H | New positive allosteric modulators of nicotinic acetylcholine receptor |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| KR101567558B1 (ko) * | 2012-06-12 | 2015-11-10 | 동국대학교 산학협력단 | Ｃ형 간염 바이러스의 게놈 복제의 선택적 저해 활성을 갖는 인돌계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물 |
| JP6249952B2 (ja) * | 2012-10-16 | 2017-12-20 | 武田薬品工業株式会社 | 複素環化合物 |
| CA2898690C (en) * | 2013-01-25 | 2020-12-29 | Compagnie Gervais Danone | Process for preparing strained fermented dairy product |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| US10408748B2 (en) * | 2017-01-26 | 2019-09-10 | ClariFruit | System and method for evaluating fruits and vegetables |
| CN106977504A (zh) * | 2017-04-06 | 2017-07-25 | 济南大学 | 一种1,2,4‑恶二唑衍生物、制备方法及其医药用途 |
| CN109374574A (zh) * | 2018-12-20 | 2019-02-22 | 中国烟草总公司郑州烟草研究院 | 一种利用近红外光谱信息鉴别烤烟烟叶蜡质感的方法 |
| CN109374575A (zh) * | 2018-12-20 | 2019-02-22 | 中国烟草总公司郑州烟草研究院 | 一种基于近红外光谱分析技术的烤烟烟叶底色的鉴别方法 |
| CA3141405A1 (en) * | 2019-06-12 | 2020-12-17 | H. Charles Manning | Amino acid transport inhibitors and the uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US199142A (en) * | 1878-01-15 | Improvement in draft-equalizers | ||
| DE3939238A1 (de) * | 1989-11-28 | 1991-05-29 | Bayer Ag | Heterocyclisch substituierte acrylsaeureester |
| DE4002466A1 (de) * | 1990-01-28 | 1991-10-10 | Bayer Ag | Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester |
| US5262416A (en) * | 1990-01-28 | 1993-11-16 | Bayer Aktiengesellschaft | Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters |
| US5462943A (en) * | 1990-01-28 | 1995-10-31 | Bayer Aktiengesellschaft | Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides |
| US5523312A (en) * | 1994-09-27 | 1996-06-04 | Sterling Winthrop Inc. | Antipicornaviral agents |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| EP1697333A4 (en) * | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR |
| GB0413613D0 (en) * | 2004-06-17 | 2004-07-21 | Univ London | Small molecule carriers |
| CA2583681A1 (en) * | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| NZ560513A (en) * | 2005-02-25 | 2010-07-30 | Ono Pharmaceutical Co | Indole compound and use thereof |
| US7605269B2 (en) * | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
| WO2006115188A1 (ja) * | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | ヘテロ環化合物 |
| WO2006131336A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| BRPI0615133A2 (pt) * | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| EP2109364A4 (en) * | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| US20080280786A1 (en) * | 2007-05-07 | 2008-11-13 | Halliburton Energy Services, Inc. | Defoamer/antifoamer compositions and methods of using same |
| EP3782991A1 (en) * | 2008-05-14 | 2021-02-24 | The Scripps Research Institute | Novel modulators of sphingosine phosphate receptors |
| UY31922A (es) * | 2008-06-20 | 2010-01-05 | Glaxo Group Ltd | Compuestos |
-
2009
- 2009-06-18 UY UY0001031922A patent/UY31922A/es not_active Application Discontinuation
- 2009-06-18 EP EP09765886A patent/EP2297139A1/en not_active Withdrawn
- 2009-06-18 US US12/999,091 patent/US8217028B2/en not_active Expired - Fee Related
- 2009-06-18 TW TW098120346A patent/TW201011013A/zh unknown
- 2009-06-18 JP JP2011514040A patent/JP2011524880A/ja active Pending
- 2009-06-18 US US12/486,859 patent/US20100029729A1/en not_active Abandoned
- 2009-06-18 US US12/486,853 patent/US20100010053A1/en not_active Abandoned
- 2009-06-18 WO PCT/EP2009/057597 patent/WO2009153307A1/en not_active Ceased
- 2009-06-18 AR ARP090102219A patent/AR072184A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20110086839A1 (en) | 2011-04-14 |
| EP2297139A1 (en) | 2011-03-23 |
| US20100010053A1 (en) | 2010-01-14 |
| WO2009153307A1 (en) | 2009-12-23 |
| US8217028B2 (en) | 2012-07-10 |
| TW201011013A (en) | 2010-03-16 |
| UY31922A (es) | 2010-01-05 |
| US20100029729A1 (en) | 2010-02-04 |
| JP2011524880A (ja) | 2011-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072184A1 (es) | Derivados de oxadiazol como agonistas del receptor s1p1 | |
| AR080841A1 (es) | Derivados de isoxazolina sustituida; composiciones veterinarias que los comprenden y su uso en el tratamiento de parasitos en animales | |
| AR069417A1 (es) | Piperidinas heteroaril - sustituidas | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| AR059218A1 (es) | Derivados de pirimidina | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR078786A1 (es) | Derivados de la cromenona | |
| AR070255A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1) | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| AR060401A1 (es) | Derivados de cromen-2-ona | |
| NI201200117A (es) | Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería | |
| AR066095A1 (es) | Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| PE20091811A1 (es) | DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1 | |
| AR072188A1 (es) | Compuestos de sulfonamida ciclicos, procedimiento para su preparacion, una composicion que los contiene, un metodo de control de plagas que lo emplea y su uso en medicina veterinaria para la proteccion contra parasitos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |